广东药科大学ESI学科动态报告(2026年05月)

作者: 时间:2026-05-19 点击数:

        2026年05月14日,ESI更新新一期数据,本期数据覆盖2016.01.01-2026.02.28共十年两个月时间。

一、广东药科大学ESI总体情况

1.我校共有5个学科入选ESI全球前1%榜单,与上期持平,5个学科中以药理学与毒理学学科的国际被引排名百分位最高(当前排名为1.73‰,与去年同期相比提升0.64个千分点),其后依次为临床医学学科、农业科学学科、化学学科、生物学与生物化学学科。

2.本期全球入榜机构总数10274个,我校排名2180,与上期相比上升了53位。按照被引总频次排名,广东药科大学排在广东省高校第18位,排名与去年同期持平。

3.本期我校被ESI收录的论文总数为7227篇,被引频次总计116863次,篇均被引频次16.17,高水平论文54篇,较上期减少5篇。单篇被引频次最高的三位作者分别是苏政权(1195次,图书馆)、王希成(690次,附属第一医院)、郭姣(676次,中医药研究所)。以广东药科大学作为第一作者或通讯作者单位的论文中,按高被引论文数量排序,前三位作者分别为郭姣(5篇)、胡坤(3篇,食品科学学院)及苏政权(2篇)。

4.本期我校有三个潜在入榜学科的潜力度超过了50%,分别为:分子生物学与遗传学(潜力度为75.09%,与去年同期相比提升12.31%个百分点)、材料科学(潜力度为68.28%,与去年同期相比提升10.17%个百分点)及免疫学(潜力度为58.95%,与去年同期相比提升14.72%个百分点)。

二、广东药科大学进入ESI全球前1%学科排名情况

1.药理学与毒理学学科。全球排名246,排名百分位17.29%(即排名为1.73‰),较上期上升2.39%,高被引论文9篇,较上期减少1篇,见表1。

表1 广东药科大学药理学与毒理学学科排名情况

ESI发布时间

论文数

总被引次数

ESI阈值

篇均被引次数

高被引论文

国内被引排名

国际被引排名

国际被引排名百分位

2026.05

1379

21776

4067

15.79

9

53/187↓

246/1423↑

17.29%↑

2026.03

1387

21456

4270

15.47

10

52/187↓

287/1458↑

19.68%↑

2026.01

1338

20207

4196

15.10

9

51/185↑

294/1432↑

20.53%↑

2025.11

1301

19218

4114

14.77

10

53/184-

300/1409↑

21.29%↑

2025.09

1263

18231

3989

14.43

8

53/182↑

306/1389↑

22.03%↑

2025.07

1231

17366

3945

14.11

8

54/180-

313/1370↑

22.85%↑

2025.05

1191

16418

3865

13.79

8

54/175↑

320/1351↑

23.69%↑

2.临床医学学科。全球排名2703,排名百分位39.08%,较上期下降1.12%,高被引论文22篇,较上期减少2篇,见表2。

表2 广东药科大学临床医学学科排名情况

ESI发布时间

论文数

总被引次数

ESI阈值

篇均被引次数

高被引论文

国内被引排名

国际被引排名

国际被引排名百分位

2026.05

1375

20314

4090

14.77

22

128/286↓

2703/6916↓

39.08%↓

2026.03

1377

21005

4541

15.25

24

127/269-

2692/7091↑

37.96%↑

2026.01

1331

19845

4392

14.91

21

127/267↓

2706/6966↑

38.85%↑

2025.11

1284

18933

4342

14.75

18

125/262-

2717/6860↑

39.61%↑

2025.09

1244

18090

4288

14.54

21

125/259↑

2731/6754↑

40.44%↑

2025.07

1218

17287

4284

14.19

17

126/256↑

2756/6654↑

41.42%↑

2025.05

1180

16394

4269

13.89

13

128/247↓

2794/6557↓

42.61%↓

3.农业科学学科。全球排名680,排名百分位47.32%,较上期下降2.13%,高被引论文5篇,较上期减少2篇,见表3。

表3 广东药科大学农业科学学科排名情况

ESI发布时间

论文数

总被引次数

ESI阈值

篇均被引次数

高被引论文

国内被引排名

国际被引排名

国际被引排名百分位

2026.05

407

8792

3669

21.60

5

145/279↓

680/1437↓

47.32%↓

2026.03

404

9596

3808

23.75

7

135/274↓

662/1465↑

45.19%↑

2026.01

387

9097

3740

23.51

6

133/264↓

664/1429↑

46.47%↑

2025.11

379

8727

3640

23.03

6

132/258↓

665/1405↓

47.33%↑

2025.09

364

8430

3558

23.16

6

130/251↓

664/1381↓

48.08%↑

2025.07

354

8134

3506

22.98

6

127/250↓

661/1359↑

48.64%↑

2025.05

348

7756

3409

22.29

6

126/245-

666/1332↑

50.00%↑

4.化学学科。全球排名1065,排名百分位47.65%,较上期下降0.13%,高被引论文1篇,与上期持平,见表4。

表4 广东药科大学化学学科排名情况

ESI发布时间

论文数

总被引次数

ESI阈值

篇均被引次数

高被引论文

国内被引排名

国际被引排名

国际被引排名百分位

2026.05

1473

22532

7709

15.30

1

259/458↓

1065/2235↑

47.65%↓

2026.03

1528

24041

7962

15.73

1

253/456↓

1081/2275↑

47.52%↑

2026.01

1487

22865

7909

15.38

2

251/442↓

1087/2222↑

48.92%↑

2025.11

1454

21934

7891

15.09

1

249/429-

1090/2179↑

50.02%↑

2025.09

1427

21208

7883

14.86

1

249/423↓

1094/2141↓

51.10%↑

2025.07

1395

20580

7930

14.75

1

248/414↓

1092/2106↑

51.85%↑

2025.05

1357

19704

7752

14.52

0

245/402↓

1094/2069↑

52.88%↓

5.生物学与生物化学学科。全球排名1118,排名百分位66.11%,较上期上升2.33%,高被引论文2篇,较上期减少1篇,见表5。

表5 广东药科大学生物学与生物化学学科排名情况

ESI发布时间

论文数

总被引次数

ESI阈值

篇均被引次数

高被引论文

国内被引排名

国际被引排名

国际被引排名百分位

2026.05

647

12317

7284

19.04

2

141/225↑

1118/1691↑

66.11%↑

2026.03

649

12440

7603

19.17

3

144/223-

1186/1733↑

68.44%↑

2026.01

620

11806

7436

19.04

2

144/216↓

1190/1701↑

69.96%↑

2025.11

603

11277

7307

18.7

4

143/210↓

1195/1674↑

71.39%↑

2025.09

587

10805

7184

18.41

3

142/206↓

1201/1649↑

72.83%↑

2025.07

569

10377

7130

18.24

3

141/204-

1213/1623↑

74.74%↑

2025.05

546

9885

6956

18.10

1

141/201↑

1220/1599↑

76.30%↑

三、广东药科大学高被引论文情况

本期广东药科大学共有54篇高被引论文,较上期减少5篇;其中广东药科大学作为第一作者或通讯作者单位的论文有25篇。以广东药科大学作为第一作者或通讯作者单位的25篇论文中,按照高被引论文数量排序,前三位作者分别为郭姣(5篇)、胡坤(3篇)及苏政权(2篇);按照作者高被引论文总被引频次排序,前五位作者分别为郭姣(2356次)、苏政权(1259次)、胡坤(652次)、龙晓英(283次)及刘伟(222次)。广东药科大学高被引论文的具体信息见表6(以被引频次排名)。

表6 广东药科大学高被引论文

序号

题名

广东药科大学作者

来源期刊

学 科

被引频次

出版年

1

THE PI3K/AKT PATHWAY IN OBESITY AND TYPE 2 DIABETES

苏政权(通讯作者)

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES 14 (11): 1483-1496 2018

BIOLOGY & BIOCHEMISTRY

1195

2018

2

GEMCITABINE AND CISPLATIN INDUCTION CHEMOTHERAPY IN NASOPHARYNGEAL CARCINOMA

王希成(第十四作者)

NEW ENGLAND JOURNAL OF MEDICINE 381 (12): 1124-1135 SEP 19 2019

CLINICAL MEDICINE

690

2019

3

M2B MACROPHAGE POLARIZATION AND ITS ROLES IN DISEASES

郭姣(通讯作者)

JOURNAL OF LEUKOCYTE BIOLOGY 106 (2): 345-358 AUG 2019

IMMUNOLOGY

676

2019

4

ASSOCIATION OF BLOOD GLUCOSE CONTROL AND OUTCOMES IN PATIENTS WITH COVID-19 AND PRE-EXISTING TYPE 2 DIABETES

郭姣(通讯作者)

CELL METABOLISM 31 (6): 1068-+ JUN 2 2020

MOLECULAR BIOLOGY & GENETICS

666

2020

5

NETWORK PHARMACOLOGY IN RESEARCH OF CHINESE MEDICINE FORMULA: METHODOLOGY, APPLICATION AND PROSPECTIVE

郭姣(通讯作者)

CHINESE JOURNAL OF INTEGRATIVE MEDICINE 26 (1): 72-80 JAN 2020

CLINICAL MEDICINE

524

2020

6

ADIPOCYTE-SECRETED EXOSOMAL MICRORNA-34A INHIBITS M2 MACROPHAGE POLARIZATION TO PROMOTE OBESITY-INDUCED ADIPOSE INFLAMMATION

叶得伟(第四作者)

JOURNAL OF CLINICAL INVESTIGATION 129 (2): 834-849 FEB 1 2019

CLINICAL MEDICINE

371

2019

7

EFFECT OF FIRST-LINE SERPLULIMAB VS PLACEBO ADDED TO CHEMOTHERAPY ON SURVIVAL IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER THE ASTRUM-005 RANDOMIZED CLINICAL TRIAL

王希成(第十二作者)

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 328 (12): 1223-1232 SEP 27 2022

CLINICAL MEDICINE

361

2022

8

IN-HOSPITAL USE OF STATINS IS ASSOCIATED WITH A REDUCED RISK OF MORTALITY AMONG INDIVIDUALS WITH COVID-19

郭姣(通讯作者)

CELL METABOLISM 32 (2): 176-+ AUG 4 2020

MOLECULAR BIOLOGY & GENETICS

345

2020

9

UNDERESTIMATED HEALTH RISKS: POLYSTYRENE MICRO- AND NANOPLASTICS JOINTLY INDUCE INTESTINAL BARRIER DYSFUNCTION BY ROS-MEDIATED EPITHELIAL CELL APOPTOSIS

江俊莹(学生,第八作者)

PARTICLE AND FIBRE TOXICOLOGY 18 (1): - JUN 7 2021

PHARMACOLOGY & TOXICOLOGY

321

2021

10

RESEARCH PROGRESS ON BERBERINE WITH A SPECIAL FOCUS ON ITS ORAL BIOAVAILABILITY

龙晓英(通讯作者)

FITOTERAPIA 109: 274-282 MAR 2016

PHARMACOLOGY & TOXICOLOGY

283

2016

11

RESVERATROL ENCAPSULATION IN CORE-SHELL BIOPOLYMER NANOPARTICLES: IMPACT ON ANTIOXIDANT AND ANTICANCER ACTIVITIES

胡坤(通讯作者)

FOOD HYDROCOLLOIDS 64: 157-165 MAR 2017

AGRICULTURAL SCIENCES

262

2017

12

A COMPOSITE HYDROGEL WITH CO-DELIVERY OF ANTIMICROBIAL PEPTIDES AND PLATELET-RICH PLASMA TO ENHANCE HEALING OF INFECTED WOUNDS IN DIABETES

姚泽欣(学生,第三作者)

ACTA BIOMATERIALIA 124: 205-218 APR 1 2021

MATERIALS SCIENCE

243

2021

13

PANCREATIC CANCER: A REVIEW OF RISK FACTORS, DIAGNOSIS, AND TREATMENT

刘伟(通讯作者)

TECHNOLOGY IN CANCER RESEARCH & TREATMENT 19: - DEC 23 2020

CLINICAL MEDICINE

222

2020

14

TNF ANTAGONIST SENSITIZES SYNOVIAL FIBROBLASTS TO FERROPTOTIC CELL DEATH IN COLLAGEN-INDUCED ARTHRITIS MOUSE MODELS

秦艺菲(学生,第十作者)

NATURE COMMUNICATIONS 13 (1): - FEB 3 2022

CLINICAL MEDICINE

216

2022

15

ENHANCEMENT OF CURCUMIN WATER DISPERSIBILITY AND ANTIOXIDANT ACTIVITY USING CORE-SHELL PROTEIN-POLYSACCHARIDE NANOPARTICLES

胡坤(通讯作者)

FOOD RESEARCH INTERNATIONAL 87: 1-9 SEP 2016

AGRICULTURAL SCIENCES

198

2016

16

DUBOSIELLA NEWYORKENSIS MODULATES IMMUNE TOLERANCE IN COLITIS VIA THE L-LYSINE-ACTIVATED AHR-IDO1-KYN PATHWAY

涂舒谕(学生,第二作者)

NATURE COMMUNICATIONS 15 (1): - FEB 13 2024

IMMUNOLOGY

195

2024

17

BAICALIN PREVENTS LPS-INDUCED ACTIVATION OF TLR4/NF-?B P65 PATHWAY AND INFLAMMATION IN MICE VIA INHIBITING THE EXPRESSION OF CD14

邓向亮(通讯作者)

ACTA PHARMACOLOGICA SINICA 42 (1): 88-96 JAN 2021

PHARMACOLOGY & TOXICOLOGY

193

2021

18

ENCAPSULATION OF RESVERATROL IN ZEIN/PECTIN CORE-SHELL NANOPARTICLES: STABILITY, BIOACCESSIBILITY, AND ANTIOXIDANT CAPACITY AFTER SIMULATED GASTROINTESTINAL DIGESTION

胡坤(通讯作者)

FOOD HYDROCOLLOIDS 93: 261-269 AUG 2019

AGRICULTURAL SCIENCES

192

2019

19

PREVENTION AND TREATMENT OF COVID-19 USING TRADITIONAL CHINESE MEDICINE: A REVIEW

周良云(第三作者)

PHYTOMEDICINE 85: - MAY 2021

PHARMACOLOGY & TOXICOLOGY

171

2021

20

EFFECT OF FECAL MICROBIOTA TRANSPLANTATION ON NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED CLINICAL TRIAL

何兴祥(通讯作者)

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY 12: - JUL 4 2022

MICROBIOLOGY

162

2022

21

METRONOMIC CAPECITABINE AS ADJUVANT THERAPY IN LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA: A MULTICENTRE, OPEN-LABEL, PARALLEL-GROUP, RANDOMISED, CONTROLLED, PHASE 3 TRIAL

王希成(第十七作者)

LANCET 398 (10297): 303-313 JUL 24 2021

CLINICAL MEDICINE

160

2021

22

DRUG AFFINITY RESPONSIVE TARGET STABILITY (DARTS) ACCELERATED SMALL MOLECULES TARGET DISCOVERY: PRINCIPLES AND APPLICATION

葛跃伟(通讯作者)

BIOCHEMICAL PHARMACOLOGY 194: - DEC 2021

PHARMACOLOGY & TOXICOLOGY

154

2021

23

DRUG-MICROBIOTA INTERACTIONS: AN EMERGING PRIORITY FOR PRECISION MEDICINE

张威(通讯作者)

SIGNAL TRANSDUCTION AND TARGETED THERAPY 8 (1): - OCT 9 2023

MOLECULAR BIOLOGY & GENETICS

150

2023

24

CORDYCEPIN AMELIORATES NONALCOHOLIC STEATOHEPATITIS BY ACTIVATION OF THE AMP-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY

郭姣(通讯作者)

HEPATOLOGY 74 (2): 686-703 AUG 2021

CLINICAL MEDICINE

145

2021

25

EF24 INDUCES FERROPTOSIS IN OSTEOSARCOMA CELLS THROUGH HMOX1

林绍强(通讯作者)

BIOMEDICINE & PHARMACOTHERAPY 136: - APR 2021

PHARMACOLOGY & TOXICOLOGY

144

2021

26

TORIPALIMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH TREATMENT-NAIVE ADVANCED NON-SMALL-CELL LUNG CANCER: A MULTICENTER RANDOMIZED PHASE III TRIAL (CHOICE-01)

王希成(第六作者)

JOURNAL OF CLINICAL ONCOLOGY 41 (3): 651-+ JAN 20 2023

CLINICAL MEDICINE

142

2023

27

ADIPOCYTE-DERIVED LACTATE IS A SIGNALLING METABOLITE THAT POTENTIATES ADIPOSE MACROPHAGE INFLAMMATION VIA TARGETING PHD2

叶德伟(第十五作者)

NATURE COMMUNICATIONS 13 (1): - SEP 5 2022

CLINICAL MEDICINE

131

2022

28

UNVEILING THE THERAPEUTIC SYMPHONY OF PROBIOTICS, PREBIOTICS, AND POSTBIOTICS IN GUT-IMMUNE HARMONY

周朋君(第一作者)

FRONTIERS IN NUTRITION 11: - FEB 8 2024

CLINICAL MEDICINE

114

2024

29

FINAL OVERALL SURVIVAL ANALYSIS OF GEMCITABINE AND CISPLATIN INDUCTION CHEMOTHERAPY IN NASOPHARYNGEAL CARCINOMA: A MULTICENTER, RANDOMIZED PHASE III TRIAL

王希成(第十四作者)

JOURNAL OF CLINICAL ONCOLOGY 40 (22): 2420-+ AUG 1 2022

CLINICAL MEDICINE

110

2022

30

FERROPTOSIS: EMERGING MECHANISMS, BIOLOGICAL FUNCTION, AND THERAPEUTIC POTENTIAL IN CANCER AND INFLAMMATION

朱金容(通讯作者)

CELL DEATH DISCOVERY 10 (1): - JAN 24 2024

MOLECULAR BIOLOGY & GENETICS

105

2024

31

ASSOCIATION OF THE WEEKEND WARRIOR AND OTHER LEISURE-TIME PHYSICAL ACTIVITY PATTERNS WITH ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY A NATIONWIDE COHORT STUDY

Huang, Wentao(第七作者)

JAMA INTERNAL MEDICINE 182 (8): 840-848 AUG 2022

CLINICAL MEDICINE

102

2022

32

MULTIMODAL CELL ATLAS OF THE AGEING HUMAN SKELETAL MUSCLE

宋炎成(第十九作者)

NATURE 629 (8010): 154-+ MAY 2 2024

MOLECULAR BIOLOGY & GENETICS

102

2024

33

LUTEOLIN: A PROMISING MULTIFUNCTIONAL NATURAL FLAVONOID FOR HUMAN DISEASES

王秋红(通讯作者)

PHYTOTHERAPY RESEARCH 38 (7): 3417-3443 JUL 2024

PHARMACOLOGY & TOXICOLOGY

101

2024

34

LIBERATION OF DAIDZEIN BY GUT MICROBIAL β-GALACTOSIDASE SUPPRESSES ACETAMINOPHEN-INDUCED HEPATOTOXICITY IN MICE

覃萍(学生,第七作者)

CELL HOST & MICROBE 31 (5): 766-+ MAY 10 2023

MICROBIOLOGY

95

2023

35

PREGNANCY-INDUCED CHANGES TO THE GUT MICROBIOTA DRIVE MACROPHAGE PYROPTOSIS AND EXACERBATE SEPTIC INFLAMMATION

陈阿丽(第十二作者)

IMMUNITY 56 (2): 336-+ FEB 14 2023

IMMUNOLOGY

93

2023

36

IMMUNE CHECKPOINT INHIBITORS: BREAKTHROUGHS IN CANCER TREATMENT

张荣信(通讯作者)

CANCER BIOLOGY & MEDICINE 21 (6): 451-472 JUN 15 2024

CLINICAL MEDICINE

82

2024

37

RUTIN AMELIORATED LIPID METABOLISM DYSFUNCTION OF DIABETIC NAFLD VIA AMPK/SREBP1 PATHWAY

王艺霖(第十作者)

PHYTOMEDICINE 126: - APR 2024

PHARMACOLOGY & TOXICOLOGY

81

2024

38

KAEMPFEROL PREVENTS ACETAMINOPHEN-INDUCED LIVER INJURY BY SUPPRESSING HEPATOCYTE FERROPTOSIS VIA NRF2 PATHWAY ACTIVATION

兰天(通讯作者)

FOOD & FUNCTION 14 (4): 1884-1896 FEB 21 2023

AGRICULTURAL SCIENCES

77

2023

39

SEPSIS BIOMARKERS: ADVANCEMENTS AND CLINICAL APPLICATIONS-A NARRATIVE REVIEW

Cheng, Chen(通讯作者)

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 25 (16): - AUG 2024

CHEMISTRY

73

2024

40

MECHANISM OF ACTION OF THE BILE ACID RECEPTOR TGR5 IN OBESITY

苏政权(通讯作者)

ACTA PHARMACEUTICA SINICA B 14 (2): 468-491 FEB 2024

PHARMACOLOGY & TOXICOLOGY

64

2024

41

INFLAMMATION TRIGGERS CHONDROCYTE FERROPTOSIS IN TMJOA VIA HIF-1Α/TFRC

Wang, L. J.(第七作者)

JOURNAL OF DENTAL RESEARCH 103 (7): 712-722 JUL 2024

CLINICAL MEDICINE

52

2024

42

ICARITIN WITH AUTOPHAGY/MITOPHAGY INHIBITORS SYNERGISTICALLY ENHANCES ANTICANCER EFFICACY AND APOPTOTIC EFFECTS THROUGH PINK1/PARKIN-MEDIATED MITOPHAGY IN HEPATOCELLULAR CARCINOMA

肖炜(通讯作者)

CANCER LETTERS 587: - APR 10 2024

CLINICAL MEDICINE

50

2024

43

SELECTIVE UTILIZATION OF MEDICINAL POLYSACCHARIDES BY HUMAN GUT BACTEROIDES AND PARABACTEROIDES SPECIES

杨继(学生,第三作者)

NATURE COMMUNICATIONS 16 (1): - JAN 14 2025

BIOLOGY & BIOCHEMISTRY

45

2025

44

INTEGRATING NETWORK PHARMACOLOGY AND ANIMAL EXPERIMENTAL VALIDATION TO INVESTIGATE THE ACTION MECHANISM OF OLEANOLIC ACID IN OBESITY

胡旭光(通讯作者)

JOURNAL OF TRANSLATIONAL MEDICINE 22 (1): - JAN 21 2024

CLINICAL MEDICINE

44

2024

45

TRIPTOLIDE INDUCES APOPTOSIS AND CYTOPROTECTIVE AUTOPHAGY BY ROS ACCUMULATION VIA DIRECTLY TARGETING PEROXIREDOXIN 2 IN GASTRIC CANCER CELLS

杨文岳(学生,第九作者)

CANCER LETTERS 587: - APR 10 2024

CLINICAL MEDICINE

42

2024

46

SINGLE-CELL TRANSCRIPTOMIC ANALYSIS REVEALS GUT MICROBIOTA-IMMUNOTHERAPY SYNERGY THROUGH MODULATING TUMOR MICROENVIRONMENT

张威(第二十五作者)

SIGNAL TRANSDUCTION AND TARGETED THERAPY 10 (1): - MAY 2 2025

MOLECULAR BIOLOGY & GENETICS

35

2025

47

ISOQUERCITRIN ALLEVIATES DIABETIC NEPHROPATHY BY INHIBITING STAT3 PHOSPHORYLATION AND DIMERIZATION

Chen, Donghui(第二作者)

ADVANCED SCIENCE 12 (25): - JUL 2025

PHYSICS

27

2025

48

EPIGENETIC REGULATORY MECHANISM OF MACROPHAGE POLARIZATION IN DIABETIC WOUND HEALING (REVIEW)

Wu, Yuqing(第二作者)

MOLECULAR MEDICINE REPORTS 31 (1): - JAN 2025

CLINICAL MEDICINE

18

2025

49

TALETRECTINIB IN ROS1+ NON-SMALL CELL LUNG CANCER: TRUST

王希成(第十三作者)

JOURNAL OF CLINICAL ONCOLOGY 43 (16): - JUN 1 2025

CLINICAL MEDICINE

18

2025

50

POLYSACCHARIDE-BASED HIGH BARRIER FOOD PACKAGING FILM: DESIGN AND APPLICATION

黎珊珊(通讯作者)

CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 65 (31): 7651-7670 NOV 20 2025

AGRICULTURAL SCIENCES

18

2025

51

ULTRASOUND-ACTIVATED ERYTHROCYTE MEMBRANE-CAMOUFLAGED PT (II) LAYERED DOUBLE HYDROXIDE ENHANCES PD-1 INHIBITOR EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER THROUGH CGAS-STING PATHWAY-MEDIATED IMMUNOGENIC CELL DEATH

Liu, Wei(第五作者)

THERANOSTICS 15 (4): 1456-1477 2025

CLINICAL MEDICINE

16

2025

52

TARGETING THE ADENOSINE-MEDIATED METABOLIC IMMUNE CHECKPOINT WITH ENGINEERED PROBIOTIC FOR ENHANCED CHEMO-IMMUNOTHERAPY

Yu, Zhijie(第五作者)

ADVANCED SCIENCE 12 (15): - APR 2025

PHYSICS

16

2025

53

ATGL REGULATES RENAL FIBROSIS BY REPROGRAMMING LIPID METABOLISM DURING THE TRANSITION FROM AKI TO CKD

夏纪凯(第五作者)

MOLECULAR THERAPY 33 (2): 805-822 FEB 5 2025

CLINICAL MEDICINE

15

2025

54

ASSOCIATION BETWEEN THE CHANGES IN THE ESTIMATED GLUCOSE DISPOSAL RATE AND NEW-ONSET CARDIOVASCULAR DISEASE IN MIDDLE-AGED AND ELDERLY INDIVIDUALS: A NATIONWIDE PROSPECTIVE COHORT STUDY IN CHINA

罗丽芳(第六作者)

DIABETES OBESITY & METABOLISM 27 (4): 1859-1867 APR 2025

CLINICAL MEDICINE

10

2025

     四、广东药科大学ESI学科潜力度

表7 广东药科大学ESI学科潜力度排名

学科

排名

论文数

学科规范化的引文影响力

被引

频次

论文被引百分比

门槛值

2026年

2025年

潜力度

(05.14)

潜力度

(03.12)

潜力度

(01.08)

潜力度(11.13)

潜力度(09.11)

潜力度

(07.10)

潜力度

(05.08)

药理学与毒理学

1

1395

1.251942581

22242

87.74

4067

546.89%↑

512.58%

492.78%

481.40%

473.30%

453.54%

438.91%

临床医学

2

1388

1.331324135

20704

84.87

4090

506.21%↑

470.36%

460.47%

446.45%

432.93%

412.79%

394.33%

化学

3

1490

0.91058745

23005

88.99

7709

298.42%↓

307.74%

296.41%

286.34%

277.06%

265.86%

261.92%

农业科学

4

412

1.444664563

8961

87.62

3669

244.24%↓

256.54%

249.36%

247.01%

243.82%

238.96%

235.26%

生物学与生物化学

5

654

1.15124419

12557

86.85

7284

172.39%↑

166.20%

161.94%

158.63%

154.90%

149.44%

145.97%

分子生物学与遗传学

6

399

1.18447619

10203

87.72

13587

75.09%↑

73.61%

71.66%

69.94%

71.12%

65.42%

62.78%

材料科学

7

268

1.027036567

5776

83.96

8459

68.28%↑

66.63%

64.09%

62.67%

61.46%

59.12%

58.11%

免疫学

8

176

1.100958523

3163

84.66

5366

58.95%↑

54.56%

51.84%

49.40%

48.17%

46.10%

44.23%

环境与生态学

9

163

0.915910429

2499

85.89

5389

46.37%

46.27%

45.14%

44.18%

43.31%

41.64%

40.22%

工程学

10

128

0.944225781

1775

82.81

3869

45.88%

46.95%

44.19%

42.41%

41.04%

38.71%

37.64%

微生物学

11

172

1.070451163

2194

81.98

5519

39.75%

35.60%

33.78%

31.28%

30.16%

28.66%

26.95%

社会科学总论

12

125

1.3694296

789

80

2100

37.57%

35.03%

32.76%

32.17%

29.82%

28.35%

26.83%

植物学与动物学

13

173

0.905985549

1135

74.57

3081

36.84%

39.17%

37.44%

35.91%

34.59%

33.23%

31.82%

神经科学与行为科学

14

153

0.845981699

2046

83.66

7997

25.58%

27.44%

27.25%

26.20%

25.81%

25.14%

24.61%

精神病学与心理学

15

82

1.733931707

741

76.83

4260

17.39%

16.22%

15.33%

14.59%

13.49%

12.76%

12.02%

计算机科学

16

45

0.736084444

653

84.44

5681

11.49%

11.82%

11.94%

11.86%

11.65%

11.44%

11.54%

物理学

17

40

2.0061825

652

80

18756

3.48%

3.24%

2.92%

2.50%

2.52%

2.41%

2.32%

地球科学

18

9

0.984177778

170

100

5998

2.83%

2.60%

2.58%

2.75%

2.43%

2.38%

2.20%

数学

19

12

0.697125

38

66.67

5094

0.75%

1.44%

1.46%

1.39%

1.36%

1.31%

1.28%

多学科

20

10

0.27648

24

60

3455

0.69%

1.16%

1.14%

1.06%

1.06%

1.04%

0.94%

经济学与商学

21

10

0.7876

55

70

7941

0.69%

0.59%

0.59%

0.57%

0.54%

0.51%

0.47%